Your session is about to expire
← Back to Search
Vagus Nerve Stimulator
nVNS for Traumatic Brain Injury-Induced Acute Respiratory Distress
N/A
Recruiting
Led By Boyle Cheng, PhD
Research Sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patient has a mild-to-moderate TBI based on a non-resuscitated or post-resuscitated Glasgow Coma Scale (GCS) sum score of =>12
Patient has been admitted to the hospital for mild-to-moderate TBI that is restricted to the head and/or neck region
Must not have
Patient is receiving extracorporeal membrane oxygenation, high-frequency oscillatory ventilation (HFOV) or any form of extracorporeal lung support
Patient is receiving renal dialysis therapy for chronic renal failure
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 30 from baseline, day 60, day 90
Awards & highlights
Summary
This trial is testing a device that stimulates a nerve in the neck, along with usual medical care, to help patients with mild-to-moderate brain injuries. The goal is to prevent serious complications like severe inflammation and breathing problems.
Who is the study for?
This trial is for hospitalized patients aged 18-80 with mild-to-moderate traumatic brain injury (TBI) not on mechanical ventilation. They must have a Glasgow Coma Scale score of at least 12 and a Lung Injury Prediction Score of at least 2, indicating potential respiratory issues. Exclusions include severe lung or heart conditions, pregnancy, burns over a large body area, participation in another trial, and certain critical health statuses.
What is being tested?
The study tests non-invasive vagus nerve stimulation (nVNS) using the gammaCore Sapphire S device plus standard care against standard care alone to prevent worsening of TBI-induced respiratory distress. The goal is to avoid progression towards severe inflammation and the need for invasive breathing support within the first month after injury.
What are the potential side effects?
While specific side effects are not listed here, nVNS devices can typically cause discomfort at the site of application, headache, dizziness or changes in blood pressure. Standard care side effects depend on treatments used but may include medication reactions or complications from hospital interventions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I had a mild-to-moderate brain injury with a GCS score of 12 or more.
Select...
I was hospitalized for a mild or moderate head or neck injury.
Select...
I am between 18 and 80 years old.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am on a special lung support machine.
Select...
I am undergoing dialysis for chronic kidney failure.
Select...
I need long-term oxygen or mechanical help to breathe due to severe COPD.
Select...
I have been diagnosed with congestive heart failure.
Select...
I have burns covering 15% or more of my body.
Select...
I am not pregnant, breastfeeding, or have a positive pregnancy test.
Select...
I have moderate to severe difficulty breathing according to a specific medical standard.
Select...
I have severe liver failure.
Select...
I have been diagnosed with acute failure of the left side of my heart.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 30 from baseline, day 60, day 90
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 30 from baseline, day 60, day 90
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Days free of death
Days free of invasive mechanical ventilation
Secondary study objectives
Adverse Events/Serious Adverse Events (AEs/SAEs)
All-cause mortality
Days free of organ failure
+8 moreTrial Design
2Treatment groups
Experimental Treatment
Group I: Receiving Standard of CareExperimental Treatment1 Intervention
Patients will be managed according to the institutional best practices and SOC for TBI.
Group II: Receiving Non-invasive vagus neurostimulationExperimental Treatment2 Interventions
nVNS treatment will be applied three times daily. One treatment is defined as 2 consecutive stimulations: one, 2-minute stimulation on the side of the neck followed by a second, 2-minute stimulation on the same side of the neck. The treatment will be done 3 times per day (morning, mid-day and 1 hour before bed at night), every day, until patient is discharged from the hospital or requires mechanical ventilation. Patient will record the time they administered these treatments. If the patient is unable to do this, a research staff member who has been trained on the device can assist. Will also receive SOC for TBI.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Non-invasive vagus nerve stimulation (nVNS) works by delivering electrical impulses to the vagus nerve, which can modulate neural activity and reduce inflammation. This is particularly important for TBI patients as it may help prevent the progression of systemic inflammatory response syndrome (SIRS) and other complications such as severe respiratory distress.
By targeting the vagus nerve, nVNS can potentially stabilize autonomic functions and improve overall outcomes in TBI patients. Other common treatments for TBI include pharmacologic interventions to manage symptoms and prevent secondary injury, as well as physical and cognitive rehabilitation to support recovery.
Evaluation of current post-concussion protocols.
Evaluation of current post-concussion protocols.
Find a Location
Who is running the clinical trial?
Chuck Noll FoundationUNKNOWN
ElectroCore INCIndustry Sponsor
30 Previous Clinical Trials
2,156 Total Patients Enrolled
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)Lead Sponsor
48 Previous Clinical Trials
12,946 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a medical condition that makes it very likely you will need a breathing machine within 48 hours, or have a condition that might require immediate use of a breathing machine.I am on a special lung support machine.I am undergoing dialysis for chronic kidney failure.I need long-term oxygen or mechanical help to breathe due to severe COPD.Your Lung Injury Prediction Score (LIPS) is 2 or higher.I have been diagnosed with congestive heart failure.The patient is not expected to live for another day.I have burns covering 15% or more of my body.I am not pregnant, breastfeeding, or have a positive pregnancy test.My first nVNS treatment is scheduled within 24 hours of starting.I have moderate to severe difficulty breathing according to a specific medical standard.I had a mild-to-moderate brain injury with a GCS score of 12 or more.I was hospitalized for a mild or moderate head or neck injury.I was on a ventilator for more than 48 hours before my lung distress diagnosis.I have severe liver failure.I have been diagnosed with acute failure of the left side of my heart.I am between 18 and 80 years old.
Research Study Groups:
This trial has the following groups:- Group 1: Receiving Non-invasive vagus neurostimulation
- Group 2: Receiving Standard of Care
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger